Literature DB >> 6997968

Considerations of the risk of influenza in children and indications for prophylaxis.

W P Glezen.   

Abstract

The development of effective prophylaxis against influenza virus infections presents a special challenge. Stimulation of a protective response apparently requires more than one exposure to the virus. The virus may then change its surface antigens to render ineffective previously acquired immunity. Ideally, artificial prophylaxis should stimulate better protection than does natural infection and should anticipate antigenic change. Children experience the highest morbidity, accompanied by considerable risk, during influenza epidemics. At the same time, children in school and day care are the most important disseminators of virus in the community. Consideration should be given to providing protection for all children against influenza when effective methods and strategies have been found. Such prophylaxis would decrease not only morbidity and serious disease in children but also the risk of exposure of high-risk adult patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6997968     DOI: 10.1093/clinids/2.3.408

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  18 in total

1.  Influenza A/H1N1/09-10 infections in a NICU during the 2009-2010 H1N1 pandemic.

Authors:  Navin K Vij; Christopher C Stryker; Frank P Esper; Michael R Jacobs; Blanca E Gonzalez
Journal:  Pediatrics       Date:  2011-10-03       Impact factor: 7.124

2.  Seroprevalence of pandemic 2009 (H1N1) influenza A virus among schoolchildren and their parents in Tokyo, Japan.

Authors:  Kiyoko Iwatsuki-Horimoto; Taisuke Horimoto; Daisuke Tamura; Maki Kiso; Eiryo Kawakami; Shuji Hatakeyama; Yasuhiro Ebihara; Tomohiko Koibuchi; Takeshi Fujii; Kazuo Takahashi; Masayuki Shimojima; Yuko Sakai-Tagawa; Mutsumi Ito; Saori Sakabe; Ayaka Iwasa; Kei Takahashi; Takashi Ishii; Takeo Gorai; Koichiro Tsuji; Aikichi Iwamoto; Yoshihiro Kawaoka
Journal:  Clin Vaccine Immunol       Date:  2011-02-23

3.  Production of passive immunity in neonatal ferrets following maternal vaccination with killed influenza A virus vaccines.

Authors:  C Sweet; R A Bird; K Jakeman; D M Coates; H Smith
Journal:  Immunology       Date:  1987-01       Impact factor: 7.397

4.  Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.

Authors:  Pedro A Piedra; Manjusha J Gaglani; Mark Riggs; Gayla Herschler; Charles Fewlass; Matt Watts; Claudia Kozinetz; Colin Hessel; W Paul Glezen
Journal:  Pediatrics       Date:  2005-09       Impact factor: 7.124

5.  [Study of flu costs].

Authors:  Xavier Badia Llach; Montserrat Roset Gamisans; José M Francés Tudel; Concha Alvarez Sanz; Carlos Rubio Terrés
Journal:  Aten Primaria       Date:  2006-09-30       Impact factor: 1.137

6.  Improving influenza vaccination rates of high-risk inner-city children over 2 intervention years.

Authors:  Richard K Zimmerman; Alejandro Hoberman; Mary Patricia Nowalk; Chyongchiou J Lin; David P Greenberg; Stuart T Weinberg; Feng Shou Ko; Dwight E Fox
Journal:  Ann Fam Med       Date:  2006 Nov-Dec       Impact factor: 5.166

7.  Respiratory virus infection in hospitalized children in Austria 1979-1982. Diagnosis by immunofluorescence.

Authors:  T Popow-Kraupp; C Kunz; E Huber
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

Review 8.  Role of influenza vaccine for healthy children in the US.

Authors:  Stan L Block
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Viral diagnoses using the rapid immunofluorescence technique and epidemiological implications of acute respiratory infections among children in different European countries.

Authors:  I Orstavik; M Grandien; P Halonen; P Arstila; C H Mordhorst; A Hornsleth; T Popow-Kraupp; J McQuillin; P S Gardner; J Almeida
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

10.  Immune dysregulation in severe influenza.

Authors:  Meredith L Heltzer; Susan E Coffin; Kelly Maurer; Asen Bagashev; Zhe Zhang; Jordan S Orange; Kathleen E Sullivan
Journal:  J Leukoc Biol       Date:  2009-06       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.